Prev Close | 54.75 |
Day Low/High | 54.26 / 55.01 |
52 Wk Low/High | 42.17 / 73.23 |
Avg Volume | 3.24M |
Prev Close | 54.75 |
Day Low/High | 54.26 / 55.01 |
52 Wk Low/High | 42.17 / 73.23 |
Avg Volume | 3.24M |
Exchange | NYSE |
Shares Outstanding | 298.02M |
Market Cap | 16.32B |
EPS | 0.80 |
P/E Ratio | 2,737.50 |
Div & Yield | 1.91 (3.38%) |
Underwater positions on stocks you feel lukewarm about are prime candidates for tax selling.
CAH has managed to move above high volume resistance at the $54.50 level that has been a barrier since June.
These names combine good dividend yields with a track record of raising quarterly payouts.
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Buy Cardinal Health and give it time for the market to reassess the industry.
These stocks are selling at historically low earnings multiples, but have raised their dividends for decades.
CAH now rates as a covered call candidate.
Short-term pain should lead to long-term gains, especially for investors buying in now.
These 'bearish bets' show weak technical characteristics and have received recent quant downgrades.
Earnings season is already seeing some wacky effects.
Bitcoin, the bull market, and Amazon -- oh my! This is what you can't miss Wednesday.
The free market is going to take back control of interest rates.
The best high-yielding blue chips at discounted prices.
The Saudi Arabian economy needs to rebalance away from oil.
Blockbuster drugs still need companies to deliver them.
Other companies are starting to catch up.
I would look to begin trading it on the long side above $160.
With stocks rebounding, investors face a tough choice.
It looks like CAH will have a long road to recovery.
News of acquisition hits this high-quality stock; here's your chance.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
In a "take no pain, take no prisoners" market, health care stocks languish.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.